ISU Abxis Co. Ltd (086890) - Total Liabilities

Latest as of September 2025: ₩45.29 Billion KRW ≈ $30.69 Million USD

Based on the latest financial reports, ISU Abxis Co. Ltd (086890) has total liabilities worth ₩45.29 Billion KRW (≈ $30.69 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

ISU Abxis Co. Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how ISU Abxis Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See 086890 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

ISU Abxis Co. Ltd Competitors by Total Liabilities

The table below lists competitors of ISU Abxis Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Tirupati Forge Limited
NSE:TIRUPATIFL
India Rs472.53 Million
Gilat Telecom Global Ltd
TA:GLTL
Israel ILA63.44 Million
Ahoku Electronic Co
TW:3002
Taiwan NT$504.39 Million
Greatland Resources Limited
LSE:GGP
UK GBX371.74 Million
Haulotte Group SA
PA:PIG
France €404.55 Million
Microcosm Technology Co Ltd
TWO:3354
Taiwan NT$133.39 Million
NeueHealth Inc
NYSE:NEUE
USA $1.14 Billion
Scorpio Gold Corp
V:SGN
Canada CA$2.33 Million

Liability Composition Analysis (2014–2024)

This chart breaks down ISU Abxis Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ISU Abxis Co. Ltd (086890) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.05 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.38 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ISU Abxis Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ISU Abxis Co. Ltd (2014–2024)

The table below shows the annual total liabilities of ISU Abxis Co. Ltd from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩59.37 Billion
≈ $40.23 Million
-54.17%
2023-12-31 ₩129.55 Billion
≈ $87.79 Million
+77.81%
2022-12-31 ₩72.86 Billion
≈ $49.38 Million
-7.94%
2021-12-31 ₩79.14 Billion
≈ $53.63 Million
+102.03%
2020-12-31 ₩39.17 Billion
≈ $26.55 Million
+4.24%
2019-12-31 ₩37.58 Billion
≈ $25.47 Million
+271.87%
2018-12-31 ₩10.11 Billion
≈ $6.85 Million
-35.69%
2017-12-31 ₩15.71 Billion
≈ $10.65 Million
+10.23%
2016-12-31 ₩14.26 Billion
≈ $9.66 Million
-39.11%
2015-12-31 ₩23.41 Billion
≈ $15.87 Million
-25.87%
2014-12-31 ₩31.59 Billion
≈ $21.41 Million
--

About ISU Abxis Co. Ltd

KQ:086890 Korea Pharmaceuticals
Market Cap
$60.99 Million
₩89.99 Billion KRW
Market Cap Rank
#21177 Global
#1215 in Korea
Share Price
₩3380.00
Change (1 day)
-4.25%
52-Week Range
₩3050.00 - ₩6240.00
All Time High
₩22450.00
About

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme repla… Read more